BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 33995657)

  • 61. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
    Mitrofanova E; Unfer R; Vahanian N; Link C
    Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
    Hou P; Bojdani E; Xing M
    J Clin Endocrinol Metab; 2010 Feb; 95(2):820-8. PubMed ID: 20008023
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
    Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
    J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells.
    Kogai T; Liu YY; Mody K; Shamsian DV; Brent GA
    J Biol Chem; 2012 Jan; 287(5):3292-300. PubMed ID: 22157753
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma.
    Damle AA; Narkar AA; Badwe RA
    Indian J Exp Biol; 2011 Jun; 49(6):416-22. PubMed ID: 21702220
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
    Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
    Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
    N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells.
    Zhang GQ; Xi C; Shen CT; Song HJ; Luo QY; Qiu ZL
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37260320
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
    Read ML; Brookes K; Zha L; Manivannan S; Kim J; Kocbiyik M; Fletcher A; Gorvin CM; Firth G; Fruhwirth GO; Nicola JP; Jhiang S; Ringel MD; Campbell MJ; Sunassee K; Blower PJ; Boelaert K; Nieto HR; Smith VE; McCabe CJ
    Clin Cancer Res; 2024 Apr; 30(7):1352-1366. PubMed ID: 37921808
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
    Lavarone E; Puppin C; Passon N; Filetti S; Russo D; Damante G
    Mol Cell Endocrinol; 2013 Jan; 365(1):1-10. PubMed ID: 22982218
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells.
    Bauriaud-Mallet M; Vija-Racaru L; Brillouet S; Mallinger A; de Medina P; Rives A; Payre B; Poirot M; Courbon F; Silvente-Poirot S
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105390. PubMed ID: 31170473
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 74. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
    Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
    Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
    Choi YJ; Lee JE; Ji HD; Lee BR; Lee SB; Kim KS; Lee IK; Chin J; Cho SJ; Lee J; Lee SW; Ha JH; Jeon YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499100
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The PDZ protein SCRIB regulates sodium/iodide symporter (NIS) expression at the basolateral plasma membrane.
    Martín M; Salleron L; Peyret V; Geysels RC; Darrouzet E; Lindenthal S; Bernal Barquero CE; Masini-Repiso AM; Pourcher T; Nicola JP
    FASEB J; 2021 Aug; 35(8):e21681. PubMed ID: 34196428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer.
    Knostman KA; Cho JY; Ryu KY; Lin X; McCubrey JA; Hla T; Liu CH; Di Carlo E; Keri R; Zhang M; Hwang DY; Kisseberth WC; Capen CC; Jhiang SM
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5196-203. PubMed ID: 15472226
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
    J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis.
    Riesco-Eizaguirre G; Wert-Lamas L; Perales-Patón J; Sastre-Perona A; Fernández LP; Santisteban P
    Cancer Res; 2015 Oct; 75(19):4119-30. PubMed ID: 26282166
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
    Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
    J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.